New drug duo targets 'Hidden' colon cancer after chemo
NCT ID NCT07136077
Summary
This study is testing whether a combination of two drugs, fruquintinib and tislelizumab, can help control colorectal cancer in patients who have finished their initial chemotherapy but still have tiny amounts of cancer left in their body, detected by a special blood test. The goal is to see if this treatment can clear these hidden cancer cells and prevent the cancer from coming back. The trial will enroll about 20 patients who have completed curative treatment but show signs of minimal residual disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.